REGENXBIO To Host Conference Call on August 6 to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights – Herald-Mail Media

ROCKVILLE, Md., July 30, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAVTechnology Platform, today announced that it will host a conference call on Thursday, August 6, 2020, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2020, and recent operational highlights.

To access the live call by phone, dial (800) 708-4539 (domestic) or (800) 619-6396 (international) and enter the passcode 49857700. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at http://www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.

AboutREGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:

Tricia TruehartInvestor Relations and Corporate Communications347-926-7709ttruehart@regenxbio.com

Investors:Eleanor Barisser, 212-600-1902eleanor@argotpartners.com

Media:David Rosen, 212-600-1902david.rosen@argotpartners.com

See original here:

REGENXBIO To Host Conference Call on August 6 to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights - Herald-Mail Media

Related Posts

Comments are closed.